Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nucleix Ltd. has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 5 distinct examiners and 5 distinct art units, indicating several separate examination paths within a compact portfolio.
KIM, YOUNG J is the busiest examiner, with 2 pending matters. That repeated assignment may support targeted comparison of examiner treatment, while the other matters call for separate review of their examination contexts.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (33%) |
| §103 only | 2 (33%) |
| Double-patenting only | 1 (17%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, YOUNG J | 2 | 64.8% | +18.2% |
| PATEL, JAY M | 1 | 65.0% | +39.6% |
| VANN-OJUEKAIYE, KENDRA RAYCHELL | 1 | 0.0% | +0.0% |
| BRAZIN, JACQUELINE | 1 | 65.6% | +52.7% |
| YOUNG, BRIAN ELLIS | 1 | 65.0% | +28.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18261995 | NON-INVASIVE CANCER DETECTION BASED ON DNA METHYLATION CHANGES | KIM, YOUNG J | 13d |
| 18253272 | DETECTING METHYLATION CHANGES IN DNA SAMPLES USING RESTRICTION ENZYMES AND HIGH THROUGHPUT SEQUENCING | VANN-OJUEKAIYE, KENDRA RAYCHELL | 27d |
| 18711585 | WHOLE GENOME CPG ANALYSIS | KIM, YOUNG J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18261995 | NON-INVASIVE CANCER DETECTION BASED ON DNA METHYLATION CHANGES | KIM, YOUNG J | 13d |
| 17780227 | SYSTEMS AND DEVICES FOR SAMPLE PREPARATION AND ANALYTE DETECTION | BRAZIN, JACQUELINE | 55d |
| 19274214 | DEEP LEARNING-BASED METHODS, DEVICES, AND SYSTEMS FOR PRENATAL TESTING | PATEL, JAY M | — |
| 18711585 | WHOLE GENOME CPG ANALYSIS | KIM, YOUNG J | — |
| 17598041 | OPTIMIZED ULTRA-LOW VOLUME LIQUID BIOPSY METHODS, SYSTEMS, AND DEVICES | YOUNG, BRIAN ELLIS | — |
| Art Unit | Apps |
|---|---|
| 1681 | 2 |
| 3681 | 1 |
| 1682 | 1 |
| 1798 | 1 |
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19274214 | DEEP LEARNING-BASED METHODS, DEVICES, AND SYSTEMS FOR PRENATAL TESTING | PATEL, JAY M | 3681 | DP | Non-Final OA | — | Pending | Jul 18, 2025 |
| 18711585 | WHOLE GENOME CPG ANALYSIS | KIM, YOUNG J | 1681 | §103§112 | Non-Final OA | — | Pending | May 18, 2024 |
| 18261995 | NON-INVASIVE CANCER DETECTION BASED ON DNA METHYLATION CHANGES | KIM, YOUNG J | 1681 | §101§103§112 | Final Rejection | 13d | Pending | Jul 18, 2023 |
| 18253272 | DETECTING METHYLATION CHANGES IN DNA SAMPLES USING RESTRICTION ENZYMES AND HIGH THROUGHPUT SEQUENCING | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §101§103 | Final Rejection | 27d | Pending | May 17, 2023 |
| 17780227 | SYSTEMS AND DEVICES FOR SAMPLE PREPARATION AND ANALYTE DETECTION | BRAZIN, JACQUELINE | 1798 | §103 | Final Rejection | 55d | Pending | May 26, 2022 |
| 17598041 | OPTIMIZED ULTRA-LOW VOLUME LIQUID BIOPSY METHODS, SYSTEMS, AND DEVICES | YOUNG, BRIAN ELLIS | 1684 | §103 | Non-Final OA | — | Pending | Sep 24, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNucleix Ltd. has 6 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Young J Kim has the most, with 2 of Nucleix Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
